Valsartan and body weight
Pro Research Analysisby 
Searched over 200M research papers
Valsartan and Body Weight: Effects in Hypertensive and Obese Patients
Blood Pressure Control in Overweight and Obese Patients
Valsartan, especially when combined with amlodipine, is effective in lowering blood pressure in hypertensive patients with excess body weight. In a large study of Chinese patients, significant reductions in both systolic and diastolic blood pressure were observed across all body mass index (BMI) and waist circumference groups. The effectiveness of blood pressure control was more closely linked to BMI than waist circumference, with similar rates of blood pressure control in overweight, obese, and abdominally obese subgroups .
Impact on Body Weight and Metabolic Parameters
In hypertensive obese patients, valsartan not only reduced blood pressure but also led to a significant decrease in BMI and body weight. Over a 16-week period, valsartan treatment resulted in a reduction in BMI by about 4.7% and improved insulin sensitivity, as measured by the HOMA-IR index. Additionally, valsartan lowered plasma leptin levels, which are often elevated in obesity and linked to metabolic disturbances. These effects were not observed with felodipine, another antihypertensive agent, suggesting valsartan may offer added benefits for obesity-related metabolic issues .
Comparison with Other ARBs: Weight Gain and Fat Accumulation
When compared to telmisartan, another angiotensin II receptor blocker (ARB), valsartan did not prevent weight gain or reduce fat accumulation in animal studies. Telmisartan increased caloric expenditure, reduced visceral fat, and protected against diet-induced weight gain, while valsartan did not show these effects. Both drugs, however, influenced fat cell size, but telmisartan had a stronger impact on energy metabolism and fat reduction .
Effects in Heart Failure Patients
In patients with heart failure and reduced ejection fraction treated with sacubitril/valsartan (a combination drug including valsartan), no significant association was found between BMI and clinical outcomes such as hospitalization or mortality. This suggests that body weight does not significantly alter the effectiveness of sacubitril/valsartan in this patient group . However, a small pilot study in elderly heart failure patients found that low-dose sacubitril/valsartan was associated with a modest reduction in body weight and improved body water distribution after one month of treatment .
Valsartan and Body Weight in Animal Models
In diabetic rat models, valsartan treatment led to increased body weight compared to untreated diabetic rats, along with improved blood glucose control and reduced adverse symptoms. This suggests that valsartan may help mitigate weight loss associated with uncontrolled diabetes in animal models .
Pharmacokinetics and Body Weight in Children
In pediatric patients, the pharmacokinetics of valsartan were found to be consistent across different age and body weight groups when doses were normalized, indicating that body weight does not significantly affect how valsartan is processed in the body in children with hypertension .
Valsartan and Body Weight in Large Clinical Trials
In the NAVIGATOR study, which included a large population with impaired glucose tolerance, the relationship between body weight and physical activity was examined in the context of valsartan use. The study found that while there is a small bidirectional relationship between weight and physical activity, the effect size was minimal and not clinically significant. The study did not find a major impact of valsartan on body weight trajectories .
Conclusion
Overall, valsartan is effective for blood pressure control in overweight and obese patients and may offer modest benefits for weight and metabolic parameters in hypertensive obese individuals. However, compared to some other ARBs like telmisartan, valsartan does not appear to have strong effects on preventing weight gain or reducing fat accumulation. In heart failure and pediatric populations, valsartan’s impact on body weight is minimal or context-dependent. The available evidence suggests valsartan is a suitable antihypertensive for patients with excess body weight, with some potential metabolic advantages, but it is not a primary agent for weight loss.
Sources and full results
Most relevant research papers on this topic